The impact of HER2-Low expression in salivary duct carcinoma: Clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapy.
Kano S, Kawakita D, Honma Y, Takahashi H, Nakaguro M, Utsumi Y, Saigusa N, Hanazawa T, Tsukahara K, Okada T, Okami K, Yamazaki K, Ueki Y, Saito Y, Ozawa H, Arai T, Shimizu A, Hanyu K, Iwaki S, Imaizumi S, Sakai A, Yamauchi M, Tanaka R, Sato Y, Yamamura K, Sekimizu M, Imanishi Y, Hirai H, Sato Y, Urano M, Yamamoto H, Fushimi C, Matsuki T, Nagao T, Tada Y; Multi-institutional Joint SDC Study Group in Japan.
Kano S, et al. Among authors: fushimi c.
Oral Oncol. 2025 Jun;165:107280. doi: 10.1016/j.oraloncology.2025.107280. Epub 2025 Apr 18.
Oral Oncol. 2025.
PMID: 40252453
Free article.